Drug Profile


Alternative Names: Decitabine deoxyguanosine; Decitabine deoxyguanosine dinucleotide; S-110; SGI-110

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator SuperGen
  • Developer Astex Pharmaceuticals; Columbia University; Genentech; Groupe Francophone des Myelodysplasies; John Hopkins University; Weill Cornell Medical College
  • Class Antineoplastics; Aza compounds; Deoxyribonucleosides; Furans; Purine nucleosides; Small molecules; Triazines
  • Mechanism of Action Antimetabolites; DNA cytosine 5 methyltransferase 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Acute myeloid leukaemia; Myelodysplastic syndromes
  • Phase II Hepatocellular carcinoma; Myeloproliferative disorders; Ovarian cancer; Solid tumours
  • Phase I/II Bladder cancer; Colorectal cancer
  • Phase I Malignant melanoma; Small cell lung cancer
  • Preclinical Chronic lymphocytic leukaemia

Most Recent Events

  • 26 May 2017 National Cancer Institute plans a phase II trial for Gastrointestinal stromal tumour, Phaeochromocytoma, Paraganglioma and Renal cancer (In children, In adolescents, In adults, In elderly, Recurrent, Refractory metastatic disease, Inoperable/unresectable, Metastatic disease, Newly-diagnosed) in USA (NCT03165721)
  • 05 Apr 2017 Pharmacodynamic results from a preclinical trial in Ovarian cancer reported at the 108th Annual Meeting of the American Association for Cancer Research (AACR-2017)
  • 16 Mar 2017 Phase-III clinical trials in Acute myeloid leukaemia (Second-line therapy or greater) in Canada, USA (SC) (NCT02920008)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top